The Divisional Game: Using Procedural Rights to Impede Generic/Biosimilar Market Entry
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2195-0237
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Divisional Game: Using Procedural Rights to Impede Generic/Biosimilar Market Entry ; volume:53 ; number:7 ; day:4 ; month:8 ; year:2022 ; pages:1007-1037 ; date:8.2022
International review of intellectual property and competition law ; 53, Heft 7 (4.8.2022), 1007-1037, 8.2022
- Klassifikation
-
Recht
- Urheber
-
Foss-Solbrekk, Katarina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40319-022-01225-3
- URN
-
urn:nbn:de:101:1-2022112709113985646636
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Foss-Solbrekk, Katarina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Procedural dermatology
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Procedural dermatology
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Implementing EU consumer rights by national procedural law
Procedural rights in competition law in the EU and China
Analogical lightweight ontology of EU criminal procedural rights in judicial cooperation
Estimations of generic drug entry in Brazil using count versus ordered models
Estimations of generic drug entry in Brazil using count versus ordered models
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar